Jazz Pharmaceuticals posted strong Q1 2026 results with total revenues of $1.1 billion, a 19% increase year-over-year, driven by growth in key products like Xywav, Epidiolex, and Zepzelca. The FDA granted Priority Review for zanidatamab in first-line HER2+ gastroesophageal adenocarcinoma, with a PDUFA date set for August 25, 2026, signaling potential new treatment options. The company reaffirmed its 2026 revenue and expense guidance and highlighted ongoing pipeline advancements and business development efforts aimed at long-term growth.
Troim Tor Olav, a director at Borr Drilling Ltd, purchased 200,000 shares at $4.37 each, totaling $874,000, increasing his ownership to about 29.5 million shares. This follows a recent purchase of 500,000 shares, signaling strong insider confidence i...
Alkane Resources Limited appointed Dr. Jennifer Purdie and The Hon. Gabrielle Upton as independent Non-Executive Directors effective August 24, 2026. These appointments enhance the company's corporate governance by bringing expertise in mining, capit...
Gold Fields Limited reported earnings per share of $2.10 and revenue of $4.51 billion, both below analyst expectations. Despite this, the company showed strong operational performance with a 12% increase in gold production and an 18% rise in sales vo...
Covered call ETFs from NEOS Investments generate high income by selling options on U.S. equity indexes, with distribution rates between 12% and 14%. These ETFs perform best in volatile, range-bound markets by harvesting option premiums driven by impl...
Disney has introduced a voluntary early retirement package (VERO) for certain U.S.-based executives with at least 10 years of service and a minimum age of 50, as part of its broader restructuring efforts. Eligible employees, ranging from director to ...
